ClinicalTrials.gg
Active, not recruitingNCT06143891ROCKnrol-1Updated Oct 16, 2026

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

A Phase 3 interventional study of Belumosudil and Placebo in Chronic Graft Versus Host Disease, sponsored by Sanofi. Active, not recruiting at 151 sites in 24 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing belumosudil in Bronchiolitis Obliterans Syndrome — 7 open to participants now, 8 under way, 2 of them phase 3. belumosudil · Bronchiolitis Obliterans Syndrome.

Planned enrollment
2nd of 14
260 · median 34
Started
2024
with 3 others
Phase 3
2 of 14
1 open now
Registered
8th of 14
by date
Lead sponsor
6 of 14
Sanofi

Among the 14 studies testing belumosudil in Bronchiolitis Obliterans Syndrome, this one is the 2nd largest by planned enrollment, is one of 4 that started in 2024, is one of 2 in phase 3, and was the 8th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

7 of the 14 studies testing belumosudil in Bronchiolitis Obliterans Syndrome are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About belumosudil

belumosudil: first FDA approval 2021 (REZUROCK), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing belumosudil in Bronchiolitis Obliterans Syndrome, or all of them as a file.
02

Study summary

This is a parallel, Phase 3, two-arm study for the treatment of newly diagnosed moderate or severe chronic GVHD.

The study duration for a participant includes up to 4 weeks for screening; a treatment period until clinically meaningful cGVHD progression (defined as progression requiring addition of new systemic treatment for cGVHD), relapse/recurrence of the underlying disease, participant starts new systemic treatment for cGVHD or experiences an unacceptable toxicity, at the request of the participants or the investigators, or until the end of study is reached, whichever comes first; at least 30 days follow-up of adverse events (AEs) after the last dose until resolution or stabilization, if applicable; and long-term follow-up until death or study close-out, whichever comes first.

Read the detailed description

Up to 2.5 years

03

Conditions studied

  • Chronic Graft Versus Host Disease
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be at least 12 years of age inclusive, at the time of signing the
  • Participants who have undergone allogenic HCT with newly diagnosed moderate to severe cGVHD according to NIH consensus diagnosis and staging criteria (2014)
  • Participants who require systemic treatment with for cGVHD
  • Participants who have not received any prior systemic treatment for cGVHD (including ECP)
  • If participants are receiving other agents for the prophylaxis or treatment of acute , the dose should be under the threshold pre-defined in protocol
  • For adult participants, the body weight should be ≥40 kg. For adolescent participants, the body weight should be ≥30 kg
  • use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Participants or their legally authorized representative must be capable of giving signed informed consent

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

Medical conditions

  • Any evidence (histologic, cytogenetic, molecular, hematologic, or mixed) of progressive or underlying disease after the most recent HCT
  • Post-transplant lymphoproliferative disease within 4 weeks prior to randomization
  • Female participants who are pregnant or breastfeeding
  • Unable to tolerate a prednisone equivalent dose of ≥ 1 mg/kg/day Prior/concomitant therapy
  • Participant has had previous exposure to belumosudil.
  • Received any previous systemic treatment for cGVHD with the following exception: Corticosteroids for cGVHD received within 7 days prior to the planned administration of IMP only if in the interest of participant.

Prior/concurrent clinical study experience

  • Received any agents, or any investigational device or procedure, or prohibited therapy for this study within 28 days or 5 elimination half-lives prior to randomization, whichever is longer Diagnostic assessments
  • (if aged ≥16 years)/Lansky (if aged \<16 years) Performance Score of \< 60
  • \<25 x 109/L. Platelet transfusion is not allowed within 3 days before the screening hematological test
  • (ANC) \<0.5 x 109/L. The use of granulocyte-colony stimulating factor (G-CSF) is not allowed to reach this level during screening
  • Estimated (eGFR) \<30 mL/min/1.73 m2 using the MDRD-4 variable formula (if aged ≥18 years) or using the Bedside Schwartz formula (if aged \<18 years)
  • (AST) and/or alanine aminotransferase (ALT) >3 x without liver cGVHD or>5 × ULN with liver) cGVHD
  • Total >1.5 × (ULN) (>3 × ULN if Gilbert syndrome)
  • Participant has (FEV1) of predicted ≤39% or has lung score of 3 according to NIH consensus diagnostic and staging criteria (2014)
  • History or other evidence of severe illness or any other conditions that would make the participant, in the opinion of the Investigator, unsuitable for the study (such as malabsorption syndromes, poorly controlled psychiatric disease or coronary artery disease)
  • Known history of (HIV)
  • Active viral disease including virus (HBV) or virus (HCV)
  • Active uncontrolled cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infection. Infections are considered controlled if appropriate therapy has been instituted and, at the time of screening, no signs of infection worsening are present according to Investigator's judgement
  • Diagnosed or treated for another other than the underlying disease allogeneic HCT was indicated for, within 3 years prior to randomization with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in-situ malignancy, or low risk prostate cancer after curative therapy
  • Unable to swallow tablets
  • Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures
  • Any active, uncontrolled infections assessed to be by the Investigator
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Belumosudil

    Participants will receive belumosudil 200 mg tablets per os(PO) once daily (QD) per 28-day cycles starting on Day 1 until discontinuation criteria are met or until end of study Note: 200mg two times a day (BID) is used in some cases, when the subject is taking a proton pump inhibitor or a strong CYP3A4 inducer)

    Drug: Belumosudil · Drug: Prednisone · Drug: Prednisolone

  • Placebo comparator
    Placebo

    Participants will receive matching placebo tablets PO QD per 28-day cycles starting on Day 1 until discontinuation criteria are met or until end of study

    Drug: Placebo · Drug: Prednisone · Drug: Prednisolone

Interventions

  • Pharmaceutical form:Tablet-Route of administration:oral

    Also known as: SAR445761/ KD025, REZUROCK

  • DrugPlacebo

    Pharmaceutical form:Table-Route of administration:oral

  • Pharmaceutical form:Tablet-Route of administration:oral

  • Pharmaceutical form:Tablet-Route of administration:oral

06

What researchers measure

Primary outcomes

  1. Event-Free Survival (EFS)

    From the date of randomization to the date of any predefined event, whichever occurs first

    Time frame: Until the end of the study (up to 2.5 years since first patient in).

Secondary outcomes

  1. Modified Lee Symptom Scale (mLSS)

    Proportion of participants who achieve a clinically relevant reduction in mLSS of at least 6 points from baseline (Only in participants at least 18 years of age)

    Time frame: Until the end of the study (up to 2.5 years since first patient in).

  2. Durable overall response rate

    Proportion of participants who achieve an overall response (PR or CR) as per 2014 NIH consensus response criteria by 48 weeks and maintained the response for a duration of at least 6 months

    Time frame: Until the end of the study (up to 2.5 years since first patient in).

  3. Rate of corticosteroid withdrawal

    Proportion of participants who successfully discontinue all systemic corticosteroids for cGVHD for at least 30 days before the occurrence of cGVHD progression, or start of a new systemic treatment for cGVHD, relapse or recurrence of the underlying disease, or unacceptable toxicity

    Time frame: Until the end of the study (up to 2.5 years since first patient in).

  4. Overall response rate (ORR)

    Proportion of participants who achieve an overall response (CR or PR) as per 2014 NIH consensus response criteria at any time before the start of new systemic treatment for cGVHD

    Time frame: Until the end of the study (up to 2.5 years since first patient in).

  5. ORR by 24 weeks

    Proportion of participants who achieve an overall response (CR or PR) as per 2014 NIH consensus response criteria by 24 weeks (Cycle 7 Day 1) before the start of new systemic treatment for cGVHD

    Time frame: Until the end of the study (up to 2.5 years since first patient in).

  6. Duration of response (DOR)

    Time from the date of the first response to the date of cGVHD progression, start of new systemic treatment for cGVHD, or death, whichever occurs first. DOR is determined only for participants who achieved overall response (PR or CR) as per 2014 NIH consensus response criteria

    Time frame: Until the end of the study (up to 2.5 years since first patient in).

  7. Dose reduction in corticosteroid

    Proportion of participants with a reduction in daily corticosteroid dose

    Time frame: Until the end of the study (up to 2.5 years since first patient in).

  8. Failure Free Survival (FFS)

    Failure Free Survival (FFS) is defined as the time from the date of randomization to the date of start of a new systemic treatment for cGVHD, relapse or recurrence of the underlying disease, or death, whichever occurs first.

    Time frame: Until the end of the study (up to 2.5 years since first patient in).

  9. Change in patient reported outcome (PRO)

    Change from baseline in Patient-Reported Outcomes Measurement Information System Global Health (PROMIS-GH) (Only in participants at least 18 years of age) and the European Quality of Life Group Questionnaire with 5 Dimensions and 5 Levels (EQ5D5L)

    Time frame: Until the end of the study (up to 2.5 years since first patient in).

  10. Number of participants with treatment-emergent adverse events [TEAEs], serious TEAEs, and adverse events of special interest (AESIs)

    Time frame: Until the end of the study (up to 2.5 years since first patient in).

  11. Overall survival

    The time from the date of randomization to the date of death due to any cause

    Time frame: Until the end of the study (up to 2.5 years since first patient in).

  12. Time to response (TTR)

    Time to Response is defined as the time from randomization to the date the patient has first response (CR or PR).

    Time frame: Until the end of study (up to 2.5 years since first patient in)

  13. Response by organ

    Proportion of participants who achieve CR or PR as per NIH consensus response criteria (2014) at any time point in each involved organ and before the start of a new systemic therapy for cGVHD.

    Time frame: Until the end of study (up to 2.5 years since first patient in)

07

Study locations

151 sites
  • University of Arkansas for Medical Sciences-Site Number : 8400019
    Little Rock, Arkansas 72205, United States
  • City of Hope National Medical Center- Site Number : 8400001
    Duarte, California 91010, United States
  • University of California San Francisco - Parnassus Heights- Site Number : 8400035
    San Francisco, California 94143, United States
  • AdventHealth Orlando- Site Number : 8400023
    Orlando, Florida 32803, United States
  • The Hope Clinic of Emory University- Site Number : 8400020
    Decatur, Georgia 30030, United States
  • Northwestern University- Site Number : 8400017
    Chicago, Illinois 60611, United States
  • Indiana University Health University Hospital- Site Number : 8400006
    Indianapolis, Indiana 46202, United States
  • University of Kentucky Chandler Medical Center- Site Number : 8400024
    Lexington, Kentucky 40536, United States
  • Johns Hopkins Hospital- Site Number : 8400033
    Baltimore, Maryland 21287, United States
  • Dana Farber Cancer Institute Site Number : 8400005
    Boston, Massachusetts 02115, United States
  • Karmanos Cancer Institute - Detroit- Site Number : 8400013
    Detroit, Michigan 48201, United States
  • UNC Children's Hospital- Site Number : 8400025
    Chapel Hill, North Carolina 27514, United States
  • Atrium Health Wake Forest Baptist Medical Center - Winston-Salem - Medical Center Boulevard- Site Number : 8400007
    Winston-Salem, North Carolina 27157, United States
  • Oncology Hematology Care - Kenwood- Site Number : 8400030
    Cincinnati, Ohio 45236, United States
  • The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute- Site Number : 8400026
    Columbus, Ohio 43210, United States
  • Oregon Health and Science University- Site Number : 8400027
    Portland, Oregon 97239, United States
  • UPMC Hillman Cancer Center- Site Number : 8400008
    Pittsburgh, Pennsylvania 15232, United States
  • Sarah Cannon Research Institute Site Number : 8400003
    Nashville, Tennessee 37203, United States
  • St. David's South Austin Medical Center- Site Number : 8400002
    Austin, Texas 78704, United States
  • Texas Oncology - Dallas - Worth Street- Site Number : 8400010
    Dallas, Texas 75246, United States
  • Texas Transplant Institute - Methodist Hospital- Site Number : 8400037
    San Antonio, Texas 78229, United States
  • University of Virginia Comprehensive Cancer Center-Site Number : 8400031
    Charlottesville, Virginia 22903, United States
  • Fred Hutchinson Cancer Research Center- Site Number : 8400004
    Seattle, Washington 98109, United States
  • University of Wisconsin Carbone Cancer Center-Site Number : 8400029
    Madison, Wisconsin 53792, United States
  • Investigational Site Number : 0320006
    Pilar, Buenos Aires 1629, Argentina
  • Investigational Site Number : 0320005
    Buenos Aires, 1227, Argentina
  • Investigational Site Number : 0320003
    Buenos Aires, 1280, Argentina
  • Investigational Site Number : 0320001
    Buenos Aires, 1426, Argentina
  • Investigational Site Number : 0320002
    Buenos Aires, 1431, Argentina
  • Investigational Site Number : 0320004
    Córdoba, 5000, Argentina
  • Investigational Site Number : 0360005
    Westmead, New South Wales 2145, Australia
  • Investigational Site Number : 0360003
    Brisbane, Queensland 4029, Australia
  • Investigational Site Number : 0360001
    Melbourne, Victoria 3000, Australia
  • Investigational Site Number : 0360004
    Murdoch, Western Australia 6150, Australia
  • Investigational Site Number : 0400003
    Graz, 8036, Austria
  • Investigational Site Number : 0400001
    Linz, 4020, Austria
  • Investigational Site Number : 0400004
    Vienna, 1090, Austria
  • Cliniques Universitaires St. Luc-Investigational Site Number : 0560005
    Woluwe, Brussels Capital 1200, Belgium
  • UZ Leuven-Investigational Site Number : 0560001
    Leuven, Vlaams-Brabant 3000, Belgium
  • Investigational Site Number : 0560006
    Bruges, 8000, Belgium
  • UZ Gent-Investigational Site Number : 0560003
    Ghent, 9000, Belgium
  • CHU de Liège-Investigational Site Number : 0560004
    Liège, 4000, Belgium
  • AZ Delta-Investigational Site Number : 0560002
    Roeselare, 8800, Belgium
  • Hospital de Clinicas da Universidade Federal do Parana- Site Number : 0760008
    Curitiba, Paraná 80060-900, Brazil
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto- Site Number : 0760006
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • INCA - Hospital do Câncer - Rio de Janeiro - Praça Da Cruz Vermelha- Site Number : 0760007
    Rio de Janeiro, 20230-130, Brazil
  • Hospital das Clinicas FMUSP- Site Number : 0760004
    São Paulo, 05403-000, Brazil
  • Hospital Israelita Albert Einstein- Site Number : 0760003
    São Paulo, 05651-901, Brazil
  • Investigational Site Number : 1240007
    Calgary, Alberta T2N 5G2, Canada
  • Investigational Site Number : 1240005
    Toronto, Ontario M5G 2M9, Canada
  • Hôpital Maisonneuve Rosemont-Investigational Site Number : 1240001
    Montreal, Quebec H1T 2M4, Canada
  • CHU Sainte-Justine-Site Number : 1240003
    Montreal, Quebec H3T1C5, Canada
  • Investigational Site Number : 1240002
    Montreal, Quebec H4A 3J1, Canada
  • Investigational Site Number : 1240008
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Investigational Site Number : 1560019
    Beijing, 100050, China
  • Investigational Site Number : 1560012
    Changchun, 130021, China
  • Investigational Site Number : 1560010
    Changsha, 410008, China
  • Investigational Site Number : 1560011
    Fuzhou, 350001, China
  • Investigational Site Number : 1560005
    Guangzhou, 510000, China
  • Investigational Site Number : 1560002
    Hangzhou, 310003, China
  • Investigational Site Number : 1560014
    Hefei, 230001, China
  • Investigational Site Number : 1560008
    Jinan, 250001, China
  • Investigational Site Number : 1560007
    Jinan, 250014, China
  • Investigational Site Number : 1560001
    Suzhou, 215006, China
  • Investigational Site Number : 1560006
    Suzhou, 215025, China
  • Investigational Site Number : 1560003
    Tianjin, 300020, China
  • Investigational Site Number : 1560004
    Tianjin, 300020, China
  • Investigational Site Number : 1560013
    Wuhan, 430022, China
  • Investigational Site Number : 1560015
    Wuhan, 430030, China
  • Investigational Site Number : 1560009
    Zhengzhou, 450008, China
  • Interni hematologicka a onkologicka klinika Fakultni nemocnice Brno-Site Number : 2030003
    Brno, 62500, Czechia
  • IV. Interni hematologicka klinika, Fakultni nemocnice Hradec Kralove-Site Number : 2030002
    Hradec Králové, 50005, Czechia
  • Klinika hematoonkologie, Fakultni nemocnice Ostrava-Site Number : 2030001
    Ostrava, 70852, Czechia
  • Ustav hematologie a krevni transfuze-Site Number : 2030004
    Prague, 128 00, Czechia
  • Rigshospitalet Copenhagen University Hospital-Investigational Site Number : 2080002
    Copenhagen, Capital 2100, Denmark
  • Odense University Hospital-Investigational Site Number : 2080003
    Odense, Funen 5000, Denmark
  • Department of hematology-Investigational Site Number : 2080001
    Aarhus, Jutland 8200, Denmark
  • Institut Paoli Calmettes-Investigational Site Number : 2500004
    Marseille, 13273, France
  • CHU Hotel Dieu-Investigational Site Number : 2500005
    Nantes, 44093, France
  • Investigational Site Number : 2500003
    Paris, 75010, France
  • Investigational Site Number : 2500001
    Paris, 75571, France
  • CHU Bordeaux-Hôpital Haut-Lévêque-Investigational Site Number : 2500002
    Pessac, 33600, France
  • Hôpital Lyon Sud-Investigational Site Number : 2500007
    Pierre-Bénite, 69310, France
  • Hôpital Pontchaillou - CHU de Rennes-Investigational Site Number : 2500008
    Rennes, 35033, France
  • Investigational Site Number : 2500006
    Vandœuvre-lès-Nancy, 54511, France
  • Investigational Site Number : 2760007
    Berlin, 13353, Germany
  • Investigational Site Number : 2760003
    Cologne, 50937, Germany
  • Investigational Site Number : 2760001
    Dresden, 01307, Germany
  • Investigational Site Number : 2760005
    Freiburg im Breisgau, 79106, Germany
  • Investigational Site Number : 2760002
    Hamburg, 20246, Germany
  • Investigational Site Number : 2760010
    Kiel, 24105, Germany
  • Investigational Site Number : 2760009
    Münster, 48149, Germany
  • Investigational Site Number : 2760006
    Regensburg, 93053, Germany
  • Investigational Site Number : 2760008
    Tübingen, 72076, Germany
  • Nosokomeio Paidon I Agia Sofia-Site Number : 3000002
    Athens, 115 27, Greece
  • General Hospital of Thessaloniki "George Papanikolaou"-Site Number : 3000001
    Thessaloniki, 570 10, Greece
  • Investigational Site Number : 3440001
    Pok Fu Lam, 999077, Hong Kong
  • Investigational Site Number : 3760002
    Haifa, 3109601, Israel
  • Investigational Site Number : 3760005
    Jerusalem, 9112001, Israel
  • Investigational Site Number : 3760006
    Petah Tikva, 4920235, Israel

Showing the first 100 of 151 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Sep 2028, 56 months after the start.

Of 30 phase 3 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's planned 56 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2023
First posted
Nov 22, 2023
StartActual
Jan 23, 2024
Primary completionEst.
Sep 29, 2028
CompletionEst.
Sep 29, 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date, site details and references
1 update, last Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Minor edits only
    + 4 other changes: identifiers, verification date, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06143891
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 22, 2023
Start date
Jan 23, 2024
Primary completion
Sep 29, 2028 (estimated)
Completion
Sep 29, 2028 (estimated)
Last update
Oct 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belumosudil

Start the discussion